. However, no study examined the clinical outcomes of an algorithm-based pharmacotherapy (ABP) including newer antipsychotics such as aripiprazole (Citrome, Kalsekar, Baker, & Hebden, 2014; Khanna et al., 2014; Robinson et al., 2015) , lurasidone (Sanford, 2013) and ziprasidone (Harrison & Scott, 2006) , which are associated with a lower risk of adverse metabolic events.
In the current study, we aimed to examine the feasibility of ABP, response, remission and treatment-resistance rates in seriously ill patients with FES in real-world clinical practice. We therefore conducted a retrospective chart review of patients who were involuntarily hospitalized and treated with an ABP that included aripiprazole as one of the first-line choices. The ABP of this study basically recommended second generation antipsychotics other than olanzapine and clozapine as first-and second-line treatments.
| METHODS

| Setting and patients
We conducted a retrospective chart review of 160 patients (continuous sampling) with the diagnosis of FES admitted to the acute inpatient ward of the Okayama Psychiatric Medical Center between October 2012 and October 2015 on involuntary status due to an imminent risk of harming themselves or others or being unable to care for themselves in the context of severe symptomatic deterioration. Our hospital is a tertiary psychiatric public hospital in a city in Japan with a population of about 700 000. Signed informed consent forms for hospital treatment were obtained from legal guardians or representatives. We had been treating patients admitted with FES based on ABP at the acute inpatient ward of our hospital. Lurasidone and ziprasidone could not be prescribed in Japan during the study period.
We defined FES as fulfilling the following criteria: (1) The Institutional Review Board of our hospital approved this study. Because data for this study were collected in the course of routine clinical care, analyzed retrospectively and anonymized, informed consent for publication was neither sought nor obtained.
| Algorithm-based pharmacotherapy
All 160 patients with FES received pharmacotherapy based on an algorithm, which aimed to save olanzapine, standardize medications, and suggest initiation of clozapine for treatment-resistant psychotic symptoms, as follows. We developed the algorithm at 3 monthly clinical conferences in which all physicians at our hospital participated, and then reminded them of it biannually thereafter. When physicians were newly employed at our hospital, we instructed them the details. 2. Dosage of antipsychotics: Antipsychotics are initiated at a lower dosage (aripiprazole, 3 to 15 mg; risperidone, 1 to 3 mg; quetiapine, 100 to 400 mg; olanzapine, 5 to 10 mg; blonanserin, 4 to 12 mg). If a patient shows no significant improvement, the dose should be titrated up to 600 mg or more equivalent to chlorpromazine. 
5.
Concomitant medications: Use of benzodiazepines (tapering after control of agitation; equivalent to lorazepam ≤8 mg) (Kitajima et al., 2012) and anticholinergic drugs (not using prophylactically; equivalent to biperiden ≤6 mg). (Ogino et al., 2011) Antidepressants and mood stabilizers are used without restriction.
| Assessments
The ICD-10 diagnosis was reconfirmed at the time of discharge through a clinical interview by the first author (B.Y.) or second author (K.S.) who oversaw the treatment and assessment during hospital treatment. Clinical ratings, routinely administered by the first or second author, included the 18-item Brief Psychiatric Rating Scale (BPRS) , (Woerner, Mannuzza, & Kane, 1988) with each item rated from 1 (not present) to 7 (extremely severe), 8 relevant items scores (delusions, P1; unusual thought contents, G9; hallucinatory behaviour, P3; conceptual disorganization, P2; mannerism/posturing, G5; blunted affect, N1; social withdrawal, N4; lack of spontaneity, N6) on the Positive and Negative Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) , the Clinical Global Impressions scale (CGI) (US Dept Health, Education, and Welfare, 1976), the Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) (Inada, 1996) and the Global Assessment of Functioning (GAF) (Jones, Thornicroft, Coffey, & Dunn, 1995) at admission and discharge. Clinical response, symptomatic remission and DIEPSS were assessed 2 weeks and 1 month after admission, then monthly thereafter. Clinical response was defined as a CGI-I score of 2 (much improved) or 1 (very much improved), and/or BPRS Thought Disorder subscale (conceptual disorganization; hallucinatory behaviour; suspiciousness; unusual thought content) score ≤6 (Agid et al., 2011) . Symptomatic remission was defined as all 8 relevant items scores in the PANSS ≤3 (mild) (Andreasen et al., 2005) . Treatment-resistance was defined as nonresponse to 2 adequate antipsychotic trials.
| Statistics
We assumed both high physician adherence and good clinical outcomes for the feasibility of ABP. Each treatment phase was defined as follows. Phase I was the first adequate antipsychotic trial. If a patient failed to tolerate an antipsychotic due to extrapyramidal symptoms, the antipsychotic was switched to another antipsychotic and the same phase restarted from the beginning. In Phase II, patients who failed to respond adequately to 1 antipsychotic trial were treated with an antipsychotic not previously tried. Patients who failed to respond to 2 adequate antipsychotic trials were offered Phase III. We used risk ratios to compare response and remission rates of different phases. Statistical analysis was conducted using IBM SPSS Statistics 24 (Chicago, Illinois). The level of significance was set at P < .05.
| RESULTS
Of 160 patients with FES who were involuntarily admitted and treated with ABP, 7 patients' records were not available for assessment, 3 patients were unable to complete even 1 adequate antipsychotic trial and 4 patients responded to electroconvulsive therapy as firstline treatment. Thus, we analyzed the medical records of 146 patients (Figure 1 ). There was no missing data of clinical ratings in 146 patients. Clinical characteristics and outcomes of patients are shown in Table 1 . Most patients (83%) were diagnosed with schizophrenia; 36% of patients had developed acutely, and 68% of patients were naïve to antipsychotic drugs. Only 5 patients (3%) had a history of substance abuse. The level of illness on admission of our sample 1 These 2 patients did not respond to 1 antipsychotic and were intolerant of 2 antipsychotics due to extrapyramidal symptoms.
2 These 3 patients did not respond to 2 antipsychotics and were intolerant of 1 antipsychotic due to extrapyramidal symptoms.
remission of the 146 patients are shown in Figure 3 . Both rates nearly stopped increasing about 4 months after admission. Table 2 shows the distribution of antipsychotics administered, the response and remission rates, and doses at the time of achieving response in each adequate trial (Phases I, II and III).
In Phase I (n = 146), aripiprazole (n = 70) was most frequently used, followed by risperidone (n = 47), quetiapine (n = 17), olanzapine (n = 11) and blonanserin (n = 1). Three patients without catatonic symptoms or intolerability were treated with olanzapine as a first-line trial. Seven of 11 patients adequately treated with olanzapine and 8 of 17 patients treated with quetiapine were switched from other previous antipsychotics due to intolerability. Few patients adequately treated with aripiprazole (n = 1) or with risperidone (n = 0) were switched. A total of 111 patients (76.0%) and 71 patients (48.6%) met the criteria for response and remission, respectively.
Before moving on to Phase II, 1 patient was discharged, and clozapine was initiated with 2 patients because they did not respond to 1 antipsychotic and were intolerant of 2 other antipsychotics due to extrapyramidal symptoms. Drug-naïve, n (%) 100 (68) Diagnosis (ICD-10) Schizophrenia (F20), n (%) 121 (83) Delusional disorder (F22), n (%) 3 (2)
Acute and transient psychotic disorder (F23), n (%) 9 (6) Schizoaffective disorder (F25), n (%) 10 (7) Other nonorganic/unspecified psychotic disorder (F28/29), n (%) 3 (2)
Previous substance abuse, n (%) 5
History of childhood epilepsy, n (%) 2 (1) Response and remission rates for Phases I (n = 146), II (n = 32) and III (n = 6) and clozapine trial (n = 9).
FIGURE 3 Cumulative rates of response and remission among 146 patients during hospitalization. 1 Median (range) duration of hospitalization was 65.5 (4 to 700) days.
In Phase II (n = 32), 1 patient without catatonic symptoms or intolerability was treated with olanzapine as a second-line trial. Surprisingly, 20 (62.5%) and 8 (25.0%) patients achieved response and remission, respectively. The response rate in Phase II was not significantly lower than that in Phase I (risk ratio = 0.82; 95% confidence interval [CI], 0.60 to 1.04; P = .12). However, the remission rate in Phase II was significantly lower than that in Phase I (risk ratio = 0.51; 95% CI, 0.27 to 0.89; P = .02). In the population and definition of this study, the treatment-resistance rate was 8.4% (12/143) at a minimum and 10.3% (15/146) at a maximum by the aforementioned results.
Before moving on to Phase III, 3 patients dropped out (discharge, n = 1; electroconvulsive therapy, n = 2), and clozapine was initiated in 3 patients because they did not respond to 2 antipsychotics and were intolerant of 1 antipsychotic.
In Phase III (n = 6), all 6 patients were adequately treated with olanzapine. Only 1 patient responded, and no patient was remitted.
Response and remission rates in Phases III and II were not compared due to the small sample size. After Phase III, 4 patients agreed to a trial of clozapine, and 1 patient continued receiving olanzapine but did not respond before discharge.
A total of 9 patients were treated with clozapine. Response and remission rates increased to 66.7% (n = 6) and 44.4% (n = 4), respec- daily dose equivalent to biperiden 0.98 AE 1.44 [0 to 5] mg), antidepressants (mirtazapine, n = 5; escitalopram, n = 3; paroxetine, n = 1; fluvoxamine, n = 1; trazodone, n = 1) and mood stabilizers (sodium valproate, n = 9; lithium, n = 7; lamotrigine, n = 2; carbamazepine, n = 1; sodium valproate + lithium, n = 1).
| DISCUSSION
Our study supports the feasibility, with high physician adherence, good clinical response and symptomatic remission rates, of an algorithm-based trial of antipsychotics of patients with FES who were involuntarily hospitalized in the acute inpatient ward. To our knowledge, this is the first report that investigated response, remission and treatment-resistance rates of those populations.
As the adequate antipsychotic treatment phase passed, response and remission rates gradually decreased. Response and remission rates were predictably high in Phase I. Unexpectedly, the response rate was not low in Phase II, but it notably decreased in Phase III. The remission rate significantly dropped in Phase II and was 0% in Phase III. However, these rates in the trial of clozapine nearly regained the level of Phase I. These results validated clozapine as a third-line trial for severely ill involuntarily admitted patients with FES.
The response rates to the first adequate antipsychotic trial (Phase I, 76.0%) and clozapine trial (66.7%) in this study were consistent with a previous observational study by Agid et al. (2011) that examined clinical outcomes in an algorithm-based approach to FES.
The present finding of a 58% remission rate at discharge is consistetnt with the previous double-blind RCT of inpatient treatment (mean AE SD duration of hospitalization, 42.92 AE 16.85 days) of acutely ill first-episode patients (Schennach-Wolff et al., 2011) . The 8.4% to 10.3% treatment-resistance rate in our study was approximately the same as the percentage of FES with persisting psychotic symptoms previously described (Edwards, Maude, McGorry, Harrigan, & Cocks, 1998; Wiersma, Nienhuis, Slooff, & Giel, 1998) .
The response rate of Phase II in this study was higher than that in an earlier study by Agid et al. (62.5% vs 16 .7%) (Agid et al., 2011) .
This discrepancy may be caused by several factors as explained below. First, inpatients constituted 100% of our sample, and thus 99% medication adherence was ensured. No patient was a pseudo non-responder due to non-or partial adherence to medication regime in our study. It is difficult to confirm accurate medication adherence of outpatients in a real-world setting (Acosta, Hernández, Pereira, Herrera, & Rodríguez, 2012; García et al., 2016) . The previous observational study including 77 outpatients and 167 inpatients might have included pseudo non-responders in the second antipsychotic trial. Second, in first-episode patients, more than 4 weeks is often needed for an adequate trial. If the duration of each treatment phase was longer, the response rate in Phase I might be higher, and that in Phase II might be lower. In the study by Gallego et al. (2011) of 112 -first-episode subjects who were randomly assigned to treatment with olanzapine or risperidone for 16 weeks, 21.8% responded by week 4, 39.6% by week 8 and 65.2% by week 16. In the RCT by Emsley, Rabinowitz, and Medori (2006) , 77.5% responded by week 4 and 88.5% by week 8 after initiation of treatment with risperidone or haloperidol of 522 patients with FES. Mean time to response with aripiprazole was 8.0 and 8.2 weeks with risperidone in the RCT for FES by Robinson et al. (2015) . However, the questions-whether it is more effective to switch to another antipsychotic or to continue the first antipsychotic if the first antipsychotic used has not worked for a patient with FES and when we should start the second antipsychotic-remain unanswered . Third, the baseline severity of patients in our study (mean CGI-S, 6.1; mean BPRS, 70.2) was greater than that in the study by Agid et al. (2011) (mean CGI-S, 5.3; mean BPRS, 57.2). The greater the baseline severity was, the greater the magnitude of symptom improvement (Furukawa et al., 2015) . The response rates to risperidone in Phases I and II of our study (87%, 86%) were higher than those in the study by Agid et al. (66%, 4%) , respectively. Fourth, aripiprazole was most frequently used, and olanzapine was saved and used mostly for patients with intolerability or catatonic symptoms in Phase I. Previous openlabel randomized prospective studies suggest that aripiprazole may be less effective than olanzapine in the acute inpatient setting (Hatta et al., 2009; McCue et al., 2006) .
Limitations of this study are the retrospective observational nature of the study in a single hospital, the lack of a control group, unblinded ratings in clinical practice, small sample sizes in Phases II and III and the trial of clozapine. However, it is difficult to conduct RCT with severely ill involuntarily hospitalized subjects from the aspect of capacity for judgment. Our algorithm followed current guidelines and recommendations to practice rational pharmacotherapy. Because we developed the algorithm through multicycle discussions among all physicians and then regularly reminded them of it, it was almost completely adhered to. Additionally, almost full medication adherence was ensured by hospital treatment over an entire period by all patients in this study. Finally, 1 specific characteristic of patients with FES in our investigation was a relatively small comorbidity of substance abuse, which potentially induces psychotic symptoms. Thus, the findings of this study would guide clinical decisions in the treatment of severely ill patients with FES without substance abuse.
In conclusion, this study suggested the validity of ABP aiming to delay olanzapine, standardize medications, and initiate clozapine for treatment-resistant psychotic symptoms for severely ill patients with FES involuntarily hospitalized. The ABP may help to prevent the delay in initiating clozapine for patients with treatment-resistant FES.
A long delay in initiating clozapine is associated with poor symptomatic improvement in treatment-resistant schizophrenia (Üçok et al., 2015; Yada, Yoshimura, & Kishi, 2015) . However, the validity of ABP was not evaluated in the strict sense of the word in this study. There was no comparison group treated as usual in this study. Additionally, we did not compare the outcomes of switching to a second-line antipsychotic and continuing with a first-line antipsychotic for nonresponders to first-line treatment for 4 weeks and did not address the applicability of clozapine as a second-line trial for non-responders to the first-line treatment for a longer period.
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